Organization
Kangpu Biopharmaceuticals
3 clinical trials
1 abstract
Clinical trial
A Phase 1, Multicenter, Open-label, Multiple-ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of KPG-818 in Subjects With Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus ErythematosusStatus: Active (not recruiting), Estimated PCD: 2023-09-22
Clinical trial
A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate CancerStatus: Completed, Estimated PCD: 2023-01-10
Abstract
KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study.Org: University of Virginia Comprehensive Cancer Center, New York Cancer and Blood Specialists, Comprehensive Cancer Centers of Nevada, Kangpu Biopharmaceuticals,